DOCSLIB.ORG

Commonly Prescribed Maintenance Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Commonly Prescribed Maintenance Medications Commonly Prescribed Maintenance Medications Maintenance (or long-term) medications are those dosage form may be used to treat more than one drugs you may take on a regular basis to treat conditions medical condition. In these cases, each medication may such as high cholesterol, high blood pressure or diabetes. be classified according to its first U.S. Food and Drug Based on your benefit plan, you may get up to a 90-day Administration (FDA) approved use. Some strengths supply of covered maintenance medication delivered and/or formulations listed may not be covered. to you through a home delivery program or at select Please note that oral contraceptives are maintenance retail pharmacies. medications and are part of this list. However, this Some plans may require you to fill these prescriptions list does not include the trade names of all available through home delivery or at select retail pharmacies oral contraceptives because there are a large number in order to receive coverage. of products. Commonly used maintenance medications are listed in Coverage is always subject to the terms and limits of this guide. This list is not all-inclusive and may change your benefit plan. Please verify with your plan if there from time to time. are any additional requirements before a drug may be Most generic drugs listed are followed by a reference covered. For details about your plan, check your benefit brand drug in (parentheses). The brand name drug materials or call the number on your member ID card. in parentheses is listed for reference and may not be Third-party brand names are the property of their covered under your benefit. Some drugs in the same respective owners. ADHD/Stimulants Allergies GALANTAMINE HYDROBROMIDE - galantamine hydrobromide oral atomoxetine hcl cap 10 mg, 18 mg, ipratropium bromide nasal soln soln 4 mg/mL 25 mg, 40 mg, 60 mg, 80 mg, 0.03% (21 mcg/spray), 0.06% 100 mg (base equivalent) (42 mcg/spray) galantamine hydrobromide tab (Strattera) 4 mg (Razadyne) Alzheimer’s Disease clonidine hcl tab er 12hr 0.1 mg galantamine hydrobromide tab ARICEPT - donepezil hydrochloride (Kapvay) 8 mg, 12 mg tab 5 mg, 10 mg, 23 mg guanfacine hcl tab er 24hr 1 mg, memantine hcl cap er 24hr 7 mg, 2 mg, 3 mg, 4 mg donepezil hydrochloride orally 14 mg, 21 mg, 28 mg (base equivalent) (Intuniv) disintegrating tab 5 mg, 10 mg (Namenda xr) INTUNIV - guanfacine hcl tab er 24hr donepezil hydrochloride tab 5 mg, memantine hcl oral solution 1 mg, 2 mg, 3 mg, 4 mg 10 mg, 23 mg (Aricept) 2 mg/mL (base equivalent) EXELON - rivastigmine td patch 24hr memantine hcl tab 5 mg, 10 mg KAPVAY - clonidine hcl tab er 12hr 4.6 mg/24hr, 9.5 mg/24hr, (Namenda) 13.3 mg/24hr 0.1 mg NAMENDA - memantine hcl tab 5 mg, STRATTERA - atomoxetine hcl cap galantamine hydrobromide cap er 10 mg 24hr 8 mg, 16 mg, 24 mg 10 mg, 18 mg, 25 mg, 40 mg, NAMENDA XR - memantine hcl cap er (Razadyne er) 60 mg, 80 mg, 100 mg 24hr 7 mg, 14 mg, 21 mg, 28 mg (base equivalent) BRAND DRUGS generic drugs 1 Commonly Prescribed Maintenance Medications NAMZARIC - memantine hcl- nitroglycerin td patch 24hr propafenone hcl tab 150 mg, donepezil hcl cap er 24hr 7-10 mg, 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 225 mg, 300 mg 14-10 mg, 21-10 mg, 28-10 mg 0.6 mg/hr (Nitro-dur) propafenone hcl cap er 12hr 225 mg, RAZADYNE - galantamine PROCARDIA - nifedipine cap 10 mg 325 mg, 425 mg (Rythmol sr) hydrobromide tab 4 mg RANEXA - ranolazine tab er 12hr quinidine gluconate tab er 324 mg RAZADYNE ER - galantamine 500 mg, 1000 mg QUINIDINE SULFATE - quinidine hydrobromide cap er 24hr 8 mg, ranolazine tab er 12hr 500 mg, sulfate tab 200 mg, 300 mg 16 mg, 24 mg 1000 mg (Ranexa) RYTHMOL SR - propafenone hcl cap rivastigmine tartrate cap er 12hr 225 mg, 325 mg, 425 mg 1.5 mg, 3 mg, 4.5 mg, 6 mg Antiarrhythmics (base equivalent) amiodarone hcl tab 100 mg, sotalol hcl tab 80 mg, 120 mg, 160 mg (Betapace) rivastigmine td patch 24hr 200 mg, 400 mg 4.6 mg/24hr, 9.5 mg/24hr, BETAPACE - sotalol hcl tab 80 mg, sotalol hcl tab 240 mg 13.3 mg/24hr (Exelon) 120 mg, 160 mg sotalol hcl (afib/afl) tab 80 mg, 120 mg, 160 mg (Betapace af) Antiangina BETAPACE AF - sotalol hcl (afib/afl) tab 80 mg, 120 mg, 160 mg SOTYLIZE - sotalol hcl oral solution CARDIZEM - diltiazem hcl tab 30 mg, DIGOXIN - digoxin oral soln 5 mg/mL 60 mg, 120 mg 0.05 mg/mL TIKOSYN - dofetilide cap 125 mcg DILATRATE SR - isosorbide dinitrate (0.125 mg), 250 mcg (0.25 mg), cap er 40 mg digoxin oral soln 0.05 mg/mL (Digoxin) 500 mcg (0.5 mg) diltiazem hcl tab 30 mg, 60 mg, digoxin tab 125 mcg (0.125 mg), 120 mg (Cardizem) Anticoagulants/Antiplatelets 250 mcg (0.25 mg) (Lanoxin) AGGRENOX - aspirin-dipyridamole diltiazem hcl tab 90 mg disopyramide phosphate cap cap er 12hr 25-200 mg ISORDIL TITRADOSE - isosorbide 100 mg, 150 mg (Norpace) dinitrate tab 5 mg, 40 mg AGRYLIN - anagrelide hcl cap 0.5 mg dofetilide cap 125 mcg (0.125 mg), anagrelide hcl cap 0.5 mg (Agrylin) isosorbide dinitrate tab 5 mg, 250 mcg (0.25 mg), 500 mcg 40 mg (Isordil titradose) (0.5 mg) (Tikosyn) anagrelide hcl cap 1 mg isosorbide dinitrate tab 10 mg, flecainide acetate tab 50 mg, aspirin-dipyridamole cap er 12hr 20 mg, 30 mg 100 mg, 150 mg 25-200 mg (Aggrenox) isosorbide mononitrate tab 10 mg, LANOXIN - digoxin tab 62.5 mcg ASPIRIN/OMEPRAZOLE – aspirin- 20 mg (0.0625 mg), 125 mcg (0.125 mg), omeprazole tab delayed release 81-40 mg, 325-40 mg isosorbide mononitrate tab er 250 mcg (0.25 mg) 24hr 30 mg, 60 mg, 120 mg MEXILETINE HCL - mexiletine hcl cap BRILINTA - ticagrelor tab 60 mg, 90 mg nifedipine cap 10 mg (Procardia), 150 mg, 200 mg, 250 mg 20 mg MULTAQ - dronedarone hcl tab cilostazol tab 50 mg, 100 mg NITRO-BID - nitroglycerin oint 2% 400 mg (base equivalent) clopidogrel bisulfate tab 75 mg NITRO-DUR - nitroglycerin td patch NORPACE - disopyramide phosphate (base equivalent) (Plavix) 24hr 0.1 mg/hr, 0.2 mg/hr, 0.3 mg/hr, cap 100 mg, 150 mg dipyridamole tab 25 mg, 50 mg, 0.4 mg/hr, 0.6 mg/hr, 0.8 mg/hr NORPACE CR - disopyramide 75 mg NITRO-TIME – nitroglycerin cap er phosphate cap er 12hr 100 mg, DURLAZA - aspirin capsule er 24hr 2.5 mg, 6.5 mg, 9 mg 150 mg 162.5 mg BRAND DRUGS generic drugs 2 Commonly Prescribed Maintenance Medications EFFIENT - prasugrel hcl tab 5 mg, bupropion hcl tab er 24hr 150 mg, FETZIMA - levomilnacipran hcl cap er 10 mg (base equivalent) 300 mg (Wellbutrin xl) 24hr 20 mg, 40 mg, 80 mg, 120 mg ELIQUIS – apixaban tab 2.5 mg BUPROPION HYDROCHLORIDE ER - (base equivalent) PLAVIX - clopidogrel bisulfate tab bupropion hcl tab er 24hr 450 mg FLUOXETINE DR - fluoxetine hcl cap 75 mg (base equivalent) CAPLYTA – lumateperone tosylate delayed release 90 mg PRADAXA - dabigatran etexilate cap 42 mg FLUOXETINE HYDROCHLORIDE - mesylate cap 75 mg, 150 mg CELEXA - citalopram hydrobromide fluoxetine hcl tab 60 mg (etexilate base equivalent) tab 10 mg, 20 mg, 40 mg fluoxetine hcl (pmdd) tab 10 mg, prasugrel hcl tab 5 mg, 10 mg (base equivalent) 20 mg (Sarafem) (base equivalent) (Effient) citalopram hydrobromide oral fluoxetine hcl cap 10 mg, 20 mg, SAVAYSA - edoxaban tosylate tab soln 10 mg/5 mL 40 mg (Prozac) 15 mg, 30 mg, 60 mg citalopram hydrobromide tab fluoxetine hcl solution 20 mg/5 mL (base equivalent) 10 mg, 20 mg, 40 mg fluoxetine hcl tab 10 mg, 20 mg (base equivalent) (Celexa) XARELTO - rivaroxaban tab 2.5 mg, fluoxetine hcl tab 60 mg 15 mg, 20 mg CYMBALTA - duloxetine hcl enteric (Fluoxetine hcl) YOSPRALA - aspirin-omeprazole tab coated pellets cap 20 mg, 30 mg, 60 mg (base equivalent) fluvoxamine maleate tab 25 mg, delayed release 81-40 mg, 50 mg, 100 mg 325-40 mg DESVENLAFAXINE ER – desvenlafaxine tab er 24hr 50 mg, fluvoxamine maleate cap er 24hr ZONTIVITY - vorapaxar sulfate tab 100 mg, 150 mg 2.08 mg (base equivalent) 100 mg FORFIVO XL - bupropion hcl tab er desvenlafaxine succinate tab er 24hr 450 mg Arterial Disease 24hr 25 mg, 50 mg, 100 mg pentoxifylline tab er 400 mg (base equivalent) (Pristiq) GEODON - ziprasidone hcl cap 20 mg, 40 mg, 60 mg, 80 mg Behavioral Health DRIZALMA SPRINKLE – duloxetine hcl cap delayed release sprinkle INVEGA - paliperidone tab er 24hr ABILIFY - aripiprazole tab 2 mg, 5 mg, 20 mg, 30 mg, 40 mg, 60 mg 1.5 mg, 3 mg, 6 mg, 9 mg 10 mg, 15 mg, 20 mg, 30 mg (base equivalent) LATUDA - lurasidone hcl tab 20 mg, ABILIFY MYCITE - aripiprazole tab duloxetine hcl enteric coated 40 mg, 60 mg, 80 mg, 120 mg 2 mg with sensor, 5 mg with sensor, pellets cap 20 mg, 30 mg, 60 mg 10 mg with sensor, 15 mg with LEXAPRO - escitalopram oxalate tab (base equivalent) (Cymbalta) sensor, 20 mg with sensor, 30 mg 5 mg, 10 mg, 20 mg with sensor duloxetine hcl enteric coated (base equivalent) pellets cap 40 mg APLENZIN - bupropion hbr tab er LITHIUM CARBONATE - lithium (base equivalent) 24hr 174 mg, 348 mg, 522 mg carbonate cap 150 mg, 600 mg EFFEXOR XR - venlafaxine hcl cap er aripiprazole oral solution 1 mg/mL lithium carbonate cap 150 mg, 24hr 37.5 mg, 75 mg, 150 mg 600 mg (Lithium carbonate) aripiprazole orally disintegrating (base equivalent) tab 10 mg, 15 mg lithium carbonate cap 300 mg EMSAM - selegiline td patch 24hr 6 lithium carbonate tab 300 mg aripiprazole tab 2 mg, 5 mg, 10 mg, mg/24hr, 9 mg/24hr, 12 mg/24hr 15 mg, 20 mg, 30 mg (Abilify) lithium carbonate tab er 300 mg escitalopram oxalate soln 5 mg/ (Lithobid) bupropion hcl tab 75 mg, 100 mg 5 mL (base equivalent) lithium carbonate tab er 450 mg bupropion hcl tab er 12hr 100 mg, escitalopram oxalate tab 5 mg, 150 mg, 200 mg (Wellbutrin sr) 10 mg, 20 mg (base equivalent) LITHIUM - lithium oral solution (Lexapro) 8 meq/5 mL BRAND DRUGS generic drugs 3 Commonly Prescribed Maintenance Medications LITHOBID
Load more

Recommended publications
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name
    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
    [Show full text]
  • An Approach to the Patient with a Dry Mouth
    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu Et Al
    US 2003O1086O2A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu et al. (43) Pub. Date: Jun. 12, 2003 (54) TABLETS AND METHODS FOR MODIFIED (22) Filed: Jul. 8, 2002 RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS Related U.S. Application Data (75) Inventors: James Shunnan Chu, Palo Alto, CA (63) Continuation of application No. 09/599,102, filed on (US); Yisong Yang, Sunnyvale, CA May 19, 2000, now Pat. No. 6,419,954. (US); Joseph A. Fix, Half Moon Bay, CA (US) Publication Classification Correspondence Address: (51) Int. Cl. ............................................... A61K 9/20 TOWNSEND AND TOWNSEND AND CREW, (52) U.S. Cl. .............................................................. 424/465 LLP TWO EMBARCADERO CENTER EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) (73) Assignee: Yamanouchi Pharma Technologies, The invention provides a tablet and methods for making the Inc., Palo Alto, CA (US) tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating (21) Appl. No.: 10/191,979 material to modify release of the active agent. Patent Application Publication Jun. 12, 2003 Sheet 1 of 11 US 2003/0108602 A1 (O) N 3(O) 2(O) A/G /A Patent Application Publication Jun. 12, 2003. Sheet 2 of 11 US 2003/0108602 A1 O / O2 OOO OO O Q(SO39 O KC O () i88. OOO OO Okk (ki (k) <k. SJS19O OO <! o O OSS) O O 33 kg) O<< 3k 32 "ooO O & : A/6, 2O Patent Application Publication Jun. 12, 2003 Sheet 3 of 11 US 2003/0108602 A1 Active POWCer (Cevimeline HCI) Formulation Parameters -Pretreatment of Active -Binder: Solid or Solution Binder -% Content of Binder (HPC or PEO/PEG) -Amount of Water Process Parameters -Equipment Selection -Spray Technique Pelletization -Product Temperature (Granulation) -Drying Procedure Process -Milling Technique -High Shear G -Fluid-Bed G In-Process Tests -Yield Active Pellet/Granules -Physical Characteristics -ASSay FIG.
    [Show full text]
  • Pediatric Pharmacotherapy
    Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 1, Number 10, October 1995 DIURETICS IN CHILDREN • Overview • Loop Diuretics • Thiazide Diuretics • Metolazone • Potassium Sparing Diuretics • Diuretic Dosages • Efficacy of Diuretics in Chronic Pulmonary Disease • Summary • References Pharmacology Literature Reviews • Ibuprofen Overdosage • Predicting Creatinine Clearance Formulary Update Diuretics are used for a wide variety of conditions in infancy and childhood, including the management of pulmonary diseases such as respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD)(1 -5). Both RDS and BPD are often associated with underlying pulmonary edema and clinical improvement has been documented with diuretic use.6 Diuretics also play a major role in the management of congestive heart failure (CHF), which is frequently the result of congenital heart disease (7). Other indications, include hypertension due to the presence of cardiac or renal dysfunction. Hypertension in children is often resistant to therapy, requiring the use of multidrug regimens for optimal blood pressure control (8). Control of fluid and electrolyte status in the pediatric population remains a therapeutic challenge due to the profound effects of age and development on renal function. Although diuretics have been used extensively in infants and children, few controlled studies have been conducted to define the pharmacokinetics and pharmacodynamics of diuretics in this population. Nonetheless, diuretic therapy has become an important part of the management of critically ill infants and children. This issue will review the mechanisms of action, monitoring parameters, and indications for use of diuretics in the pediatric population (1-5). Loop Diuretics Loop diuretics are the most potent of the available diuretics (4).
    [Show full text]
  • Primary Structure and Functional Expression of a Cdna Encoding the Thiazide-Sensitive, Electroneutral Sodium-Chloride Cotransporter GERARDO GAMBA*, SAMUEL N
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 2749-2753, April 1993 Physiology Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter GERARDO GAMBA*, SAMUEL N. SALTZBERG*t, MICHAEL LOMBARDI*, AKIHIKO MIYANOSHITA*, JONATHAN LYTTON*, MATTHIAS A. HEDIGER*, BARRY M. BRENNER*, AND STEVEN C. HEBERT*t§ *Laboratory of Molecular Physiology and Biophysics, Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Center for Study of Kidney Disease, Harvard Medical School, 75 Francis Street, Boston, MA 02115; and tMount Desert Island Biological Laboratory, Salsbury Cave, ME 04672 Communicated by Robert W. Berliner, December 17, 1992 ABSTRACT Electroneutral Na+:Cl- cotransport systems et al. (15) have identified a protein band of 185 kDa obtained are involved in a number of important physiological processes from membranes of rabbit renal cortex exposed to [3H]me- including salt absorption and secretion by epithelia and cell tolazone that may be a component of the thiazide-sensitive volume regulation. One group of Na+:Cl- cotransporters is Na+:Cl- cotransporter. specifically inhibited by the benzothiadiazine (thiazide) class of In this report we describe the sequence, functional and diuretic agents and can be distinguished from Na+:K+:2ClI pharmacological characterization, and tissue-specific expres- cotransporters based on a lack of K+ requirement and insen- sion of a cDNA clone (TSCil) encoding the electroneutral sitivity to sulfamoylbenzoic acid diuretics like bumetanide. We thiazide-sensitive Na+ :C1- cotransporter, isolated by a func- report here the isolation of a cDNA encoding a thiazide- tional expression strategy from the urinary bladder of the sensitive, electroneutral sodium-chloride cotransporter from euryhaline teleost P.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Sample Chapter
    LCMS_Chap09 (JB-D) 8/5/06 3:14 pm Page 193 9 LC-MS in doping control Detlef Thieme Introduction adjacent fields with similar analytical prospects, like veterinary residue control (predominantly dealing with identification of growth promoters Definition of doping in various matrices), forensic sciences (the major- ity of doping-relevant substances are scheduled Doping analysis comprises a diversity of sub- as controlled substances in most countries), stance classes with different pharmaceutical and environmental analysis (e.g. steroids in waste chemical properties. Therefore, the discussion of water) or clinical chemistry (e.g. due to the the suitability of liquid chromatography-mass increasing relevance of steroid hormone replace- spectrometry (LC-MS) in doping analysis needs ment therapy). to distinguish various categories. This chapter describes the key fields of appli- According to its formal definition, a doping cation of LC-MS in routine doping control (i.e. violation in sports can be caused by various screening analysis, confirmation and quantifica- events, e.g.: tion of positive results) extra to particular • the detection of a prohibited substance or research activities. The latter are focused on the metabolites or markers of that substance (as intended technical improvements (e.g. extension defined by the recent document [1] of the of detection time windows, reduction of turn- World Anti-Doping Agency [WADA]) in the around times and costs) of conventional analyti- athlete’s specimen cal procedures and, in particular, on the detection • the use of prohibited substances or methods of prohibited substances that cannot be ade- • possession or trafficking prohibited substances quately identified so far (e.g.
    [Show full text]
  • Exforge HCT in Patients with These Highlights Do Not Include All the Information Needed to Use Diabetes (4) EXFORGE HCT Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION Do not coadminister aliskiren with Exforge HCT in patients with These highlights do not include all the information needed to use diabetes (4) EXFORGE HCT safely and effectively. See full prescribing information for EXFORGE HCT. -----------------------WARNINGS AND PRECAUTIONS ----------------------- Hypotension: Correct volume depletion prior to initiation (5.2) ® EXFORGE HCT (amlodipine, valsartan, and hydrochlorothiazide) Increased angina and/or myocardial infarction (5.3) tablets, for oral use Monitor renal function and potassium in susceptible patients (5.4, 5.5) Initial U.S. Approval: 2009 Exacerbation or activation of systemic lupus erythematosus (5.7) WARNING: FETAL TOXICITY Observe for signs of fluid or electrolyte imbalance (5.9) See full prescribing information for complete boxed warning. Acute angle-closure glaucoma (5.10) When pregnancy is detected, discontinue Exforge HCT as soon as possible. (5.1) ------------------------------ADVERSE REACTIONS ------------------------------ Drugs that act directly on the renin-angiotensin system can cause Most common adverse events (≥ 2% incidence) are dizziness, peripheral injury and death to the developing fetus. (5.1) edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea, and nasopharyngitis. (6.1) ---------------------------INDICATIONS AND USAGE --------------------------- Exforge HCT is a combination tablet of amlodipine, a dihydropyridine To report SUSPECTED ADVERSE REACTIONS, contact Novartis calcium channel blocker (DHP CCB), valsartan, an angiotensin II receptor Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA- blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Exforge HCT is 1088 or www.fda.gov/medwatch. indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, ------------------------------DRUG INTERACTIONS ------------------------------ primarily strokes, and myocardial infarctions.
    [Show full text]